Next, we evaluated the effects of combination treatment in a model of primary mouse AML by transplantation of spontaneously arising FLT3/ITD;NHD13 (CD45.2+) AML cells from a mouse genetically engineered to have these mutations into syngeneic CD45.1 mice. The gene discussed is FLT3; the disease is acute myeloid leukemia.